Abstracts

Citation

Sheran Patel, D.O., Elizabeth Livingston, M.D., Ross E. McKinney, Jr., M.D., Enilda Abreu, Ph.D., Mary Jo O'Sullivan, M.D., Arlene D. Bardeguez, M.D., M.P.H., F.A.C.O.G., Jashvant D. Unadkat, Ph.D. Does Pregnancy Affect the Pharmacokinetics of Didanosine (ddi)in HIV-1 Infected Women?.

Citation

Jashvant D. Unadkat, Ph.D. Does Pregnancy after the Pharmacokinetics of (ddI) in HIV-1 Infected Women.

Citation

Michael McKenna, Zrinka Lulic, Ann M. Buchanan, Cynthia Brothers, Lionel Tan, Marcia Wang, Sean Brummel, Lauren Ziemba, Theodore Ruel, Patricia M. Flynn, Helena Rabie, Andrew Wiznia. Dolutegravir and Growth in Pediatric Populations With HIV-1: IMPAACT P1093 and IMPAACT 2019. Presented at: CROI 2024.

Citation

Nikki Mulligan, Brookie Best, Edmund Capparelli, Alice Stek, Emily Barr, Elizabeth Smith, Nahida Chakhtoura, JiaJia Wang, Sandra Burchett, Mark Mirochnick. Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women. Presented at: CROI 2016; 2016 Feb 24.

Citation

T Ruel, E Acosta, RP Singh, C Alvero, K George, S Popson, C Vavro, R Hazra, A Wiznia. Dolutegravir pharmacokinetics, safety and efficacy in HIV+ children 2 to 6 years old. Presented at: CROI 2017; 2017 Feb 16.

Citation

Dose-finding Pharmacokinetics (PK) and 24- and 48-Week Safety and Efficacy of Raltegravir (RAL) Granules for Suspension (GFS) Formulation in Human Immunodeficiency Virus type-1 (HIV)-Infected Infants Starting Treatment at 4 Wk – 6 Mo of Age.

Citation

Ada Cachafeiro, Glenn Sherman, Ph.D., A. Sohn, C. Beck-Sague, Susan A. Fiscus, Ph.D. Dried blood spots and the ultra-sensitive p24 antigen assay for the diagnosis of perinatal HIV infection. Presented at: 15th Conference on Retroviruses & Opportunistic Infections.

Citation

Allison George Agwu, M.D., Kimberly Ferguson, Jane C. Lindsey, Sc.D., Maureen M. Goodenow, Ph.D., Steven D. Douglas, M.D., Bret J. Rudy, M.D., Stephen A. Spector, M.D., Patricia M. Flynn, M.D., M.S., Deborah Persaud, M.D. Drug resistance mutations in HIV-1 infected adolescents maintained on initial HAART despite treatment failure. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Grace M. Aldrovandi, MD, Jane C. Lindsey, Sc.D., Denise Jacobson, Barbara E. Heckman, B.S., Amanda Zadzilka, B.S., John ( Jack ) Moye, Jr., M.D., Peggy R. Borum, Ph.D., William A. Meyer, III, Ph.D., Dana S. Hardin, M.D., Y. DelCarlo, Kathleen Mulligan, Ph.D. Dyslipidemia in vertically infected children and youth on protease inhibitor (PI)-containing antiretroviral therapy (ART): preliminary results of PACTG 1045. Presented at: 9th Intl Workshop on Adverse Drug Reactions & Lipodystrophy.

Citation

Margaret McManus, Mohan Somasundaran, Linda Lambrecht, Richard Hudson, Bobbie Graham, Lynne Mofenson, John L. Sullivan, Katherine Luzuriaga , PACTG 356 Investigators. Early combination antiretroviral therapy alters the persistence of HIV-1 proviruses in HIV-infected infants. Presented at: IAS 2014.